<DOC>
	<DOCNO>NCT02215980</DOCNO>
	<brief_summary>This protocol phase III multicenter , randomize , control study design ass safety efficacy standard schedule versus new algoritm dose reduction elderly unfit newly diagnose Multiple Myeloma ( MM ) patient receive lenalidomide plus steroid .</brief_summary>
	<brief_title>STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS</brief_title>
	<detailed_description>TREATMENT PERIOD : Arm A : Rd - Lenalidomide : dose 25 mg/daily oral administration ( PO ) day 1-21 . - Dexamethasone : dose 20 mg oral administration ( PO ) weekly . Each cycle repeat every 28 day progression intolerance . Arm B : Rd-R ( reduce ) - Lenalidomide : dose 25 mg/daily oral administration ( PO ) day 1-21 - Dexamethasone : dose 20 mg oral administration ( PO ) weekly . Each cycle repeat every 28 day , total 9 cycle . Maintenance progression intolerance : - Lenalidomide : 10 mg/daily day 1-21 28-day cycle</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients &gt; 65 year unfit unsuitable , accord investigator 's opinion , receive approve first line treatment newly diagnose MM . Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Symptomatic MM base standard CRAB criterion ( 5 ) . Patient measurable disease , define follow : quantifiable serum monoclonal protein value ( generally , necessarily , â‰¥ 0.5 g/dL Mprotein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour . For patient oligo nonsecretory MM , require measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) abnormal free light chain ratio ( n.v. : 0.261.65 ) . We anticipate less 10 % patient admit study oligo nonsecretory MM free light chain order maximize interpretation benefit result . All randomized patient select base use 3 geriatric scale : IADL , ADL , Charlson . Unfit patient clinical sign frailty ( mild , moderate severe frailty ) , include need help household task personal care enrol trial ( 2,4 ) . In order include patient normally select clinical trial , also patient follow abnormal laboratory value consider : 1. absolute neutrophil count ( ANC ) &lt; 1 x 10^9/L 2. platelet count &lt; 80 x 10^9/L 3. haemoglobin &lt; 8 g/dl . 4. aspartate transaminase ( AST ) : &lt; 5 x upper limit normal ( ULN ) . 5. alanine transaminase ( ALT ) : &lt; 5 x ULN . 6. total bilirubin : &gt; 1.5 x ULN 7. calculate measure creatinine clearance : &lt; 30 mL/minute The geriatric assessment evaluation select unfit patient randomize regardless possible abnormal laboratory value study entry . Pregnant lactating female . Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) duration study . Females childbearing potential agree use two acceptable method contraception ( e.g . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid &lt; equivalent dexamethasone 40 mg/day 4 day ) . Any significant medical disease condition , investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent could place subject unacceptable risk . Presence clinical active infectious hepatitis type B C , classify ChildPugh class C ( see Appendix V ) HIV . Presence acute active infection require antibiotic infiltrative pulmonary disease . Contraindication require drug supportive treatment . Presence prior history malignancy , multiple myeloma , life expectancy &lt; 2 year . Known allergy study medication , analogue , excipients various formulation .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Diagnosis</keyword>
	<keyword>Elderly unfit patient</keyword>
	<keyword>Lenalidomide plus steroid</keyword>
</DOC>